Junshi has reported positive Phase III results for its IL-17A monoclonal antibody (mAb) JS005 in moderate-to-severe plaque psoriasis, meeting all co-primary endpoints including Psoriasis Area Severity Index 90 (PASI 90) and static Physician Global Assessment (sPGA) score of 0 or 1 at week 12. The randomised double-blind study enrolled 747 patients comparing 150mg and 300mg subcutaneous doses against placebo, demonstrating significant skin clearance and favourable safety profiles. Junshi plans regulatory submissions to China's National Medical Products Administration (NMPA) imminently.

JS005 selectively blocks IL-17A binding to its receptor, reducing inflammatory cytokine release in autoimmune conditions affecting approximately 125 million patients globally. Psoriasis prevalence reaches 2.0% to 3.0% worldwide with 0.47% incidence in China, often accompanied by metabolic syndrome, cardiovascular comorbidities and psychiatric conditions. Junshi's candidate joins competitive IL-17 inhibitors including Novartis' secukinumab and Lilly's ixekizumab in this biologics-dominated market.

According to PharmCube's NextBiopharm® database, the IL-17A mAb sector that Junshi is planning to enter already has four approved products, including two from heavyweights Novartis and Eli Lilly. Click here to request a free trial for NextBiopharm®.